AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02817347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: piperacillin 4% + tazobactam 0.5%
Study NCT02125877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferasirox dispersible tablet
Description: Deferasirox DT was provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use.
Study NCT02543879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered per site's standard of care
Study NCT04605133 — intervention group
Intervention type: DEVICE
Intervention: Electrical impedance tomography
Description: Every patient is monitored with electrical impedance tomograpy before, during and after prone position.
Study NCT04715958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound
Description: Undergo CEUS
Study NCT04715958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid Microspheres
Description: Given IV
Study NCT04715958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Undergo unenhanced baseline ultrasound
Study NCT01228734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab was administered every 7 days at an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity to cetuximab.
Study NCT01228734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
Study NCT02125877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defearisox film-coated tablet
Description: Deferasirox FCT was provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
Study NCT01228734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
Study NCT01228734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
Study NCT01228734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid
Description: FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
Study NCT01228734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: 5-FU as a bolus of 400 mg/m\^2/day intravenously over 2-4 minutes followed by 600 mg/m\^2/day infusion over 22 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
Study NCT01228734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5Fluorouracil
Description: 5-FU as a bolus of 400 mg/m\^2/day intravenously over 2-4 minutes followed by 600 mg/m\^2/day infusion over 22 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
Study NCT03128099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality social skills training
Description: Participants play a virtual reality video game involving social interactions with various characters ( avatars) at a bus stop, a cafeteria and a grocery store. The games become progressively more complex as the participant improves task performance. Eye tracking patterns are recorded throughout the game to observe the patterns of social attention
Study NCT03283267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (ZS)
Description: Sodium zirconium cyclosilicate (ZS) is a non-absorbed, inorganic crystalline compound that selectively captures potassium ions in exchange for sodium and hydrogen ions in the gastrointestinal tract after oral administration.
Study NCT04258319 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound Procedure
Description: Ultrasound technique that uses a compression device integrated with ultrasound imaging to perform in vivo ramp-and-hold uniaxial creep-like test on upper extremity lymphedema (UEL) in vivo.
Study NCT04258319 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Procedure
Description: Ultrasound technique that uses a compression device integrated with ultrasound imaging to perform in vivo ramp-and-hold uniaxial creep-like test on upper extremity lymphedema (UEL) in vivo.
Study NCT01767324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injection to deltoid
Description: Deliver 0.5 milliliters of saline intradermally
Study NCT01767324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injection to forearm
Description: Deliver 0.5 milliliters of saline intradermally
Study NCT01767324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injection to thigh
Description: Deliver 0.5 milliliters of saline intradermally
Study NCT02996487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Study NCT02996487 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02448368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170,10 mg
Description: Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
Study NCT02448368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170, 2.5 mg
Description: Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
Study NCT02448368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170, 5 mg
Description: Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
Study NCT02448368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170, 10 mg
Description: Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
Study NCT02817347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: piperacillin 8% + tazobactam 1.0%
Study NCT03271047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: Orally, twice daily.
Study NCT03836885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast tablets. Titration will occur in the initial five days of treatment as per dosing in psoriasis as follows: Day 1: 10 mg; Day 2: 20 mg; Day 3: 30 mg; Day 4: 40 mg; Day 5: 50 mg. Day 6 and thereafter patients will be dosed at 60 mg for a total of 12 weeks.
Study NCT03836885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Oral tablets. Patients randomized to the control arm will receive color, taste, shape and odour matched oral placebo. The number of tablets and the days taken is analogous to the intervention arm had they been randomized to the intervention arm.
Study NCT01968824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brachial Plexus Nerve Block
Description: The brachial plexus will be visualized under ultrasound and a 22 gauge, 3.5 inch needle will be used. 20 cc of bupivicaine will be injected around the brachial plexus after confirming negative aspiration every 5 cc
Study NCT02280759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin Tannate
Study NCT02280759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consists of an identical formulation, except active substance
Study NCT03286907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online videos
Description: Watch two online short health promotion videos (five minutes each), complete a self-administered online exercise and receive reminders at month 1, 2, 4, 6 \& 8.
Study NCT03286907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online videos and MI
Description: Watch two online short health promotion videos (five minutes each), complete a self-administered online exercise, receive 15 minutes motivational interviewing through telephone and reminders at month 1, 2, 4, 6, \& 8.
Study NCT03286907 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Receive online health communication messages about prevalence of some common mental health problems among MSM and introduction of stress reduction exercises
Study NCT01002196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulus fading procedures
Description: Core elements : 1.Behavior techniques (BT's) are used to gradually master the anxiety (stimulus fading and reward).~2. Children are first met at home where they feel most safe, and the BT's are first conducted at home in cooperation with the parents.~3.The same interventions are then continued in the environment where the problem primarily exist (kindergarten / school) not at the clinic.~4.Defocused communication- and interaction is a general treatment principle (e.g. avoid looking directly at the child, sit beside not opposite to the child, no direct questioning, and communication is based upon a motivating activity, not about the child).~5.Frequent and short interventions. 6.Information to parents and teachers on how to communicate with children with SM
Study NCT01002196 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guidance on defocused communication
Description: Guidance and supervision to teachers working with the children with SM. Frequency: Twice during three months
Study NCT01002196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guidance on defocused communication
Description: Guidance and supervision to teachers working with the children with SM. Frequency: Twice during three months
Study NCT00967343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte preparation depleted of host functional alloreactive T-cells
Description: Single intravenous infusion with 2x10E6 T-cells/kg
Study NCT03977363 — intervention group
Intervention type: DRUG
Intervention: Anticoagulant drugs
Description: Anticoagulant drugs
Study NCT04019860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Three weekly, supervised exercise sessions with high intensity. Each session will last for 30-45 minutes. Intervention period will be seven weeks.
Study NCT04019860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-Restricted Eating
Description: Restricted daily window of caloric intake to maximum 10 hours. Intervention period will be seven weeks.
Study NCT02448368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170, 2.5 mg
Description: Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
Study NCT02009592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Both arms receive Rifaximin
Study NCT03271047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Intravenously (IV) every 4 weeks (Q4W)
Study NCT02008812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ad sensor
Description: Ad sensor, which was developed for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-Adenovirus and its Adenovirus antigen present in patients and normal samples.~The system incorporates the use of chip formats. In antibody probing, antibodies are bound as a suitable probe, which specifically and selectively binds targeted molecules (virus antigen) in the test specimens.
Study NCT04169152 — intervention group
Intervention type: PROCEDURE
Intervention: Cap-assisted endoscopic sclerotherapy
Description: Cap-assisted endoscopic sclerotherapy (CAES) is an innovation technique for having advantages in accurately controlling the injection angle, direction, depth under direct vision of flexible endoscope.
Study NCT01917916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for subcutaneous (s.c.) injection.
Study NCT03271047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: intravenously (IV) every 8 weeks (Q8W)
Study NCT01100528 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa-2b
Description: Given subcutaneously (SC) 3 times a week for 24 weeks
Study NCT01917916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064
Description: Solution for subcutaneous (s.c.) injection.
Study NCT05232188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy
Description: percutaneous nephrolithotomy surgery, 22F amplatz sheath is used in one group, while 28F amplatz sheath is used in the other group.
Study NCT03097146 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: comprehensive multidisciplinary stroke care
Description: Patients will be treated in the pathological domain. Some of this treatment will be applied by the outpatient clinic itself (i.e. changes in medical secondary prevention or additional prescriptions, social work interventions), whereas most of it will be referred to other providers, if possible in vicinity to the patients' home. In order to ease treatment prescriptions and allow to measure treatment uptake, patients will also enrol in the case management system Ambulanzpartner. This allows the outpatient center to streamline prescription processes and measure uptake of therapies.
Study NCT00638053 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Somatropin will be administered as a daily subcutaneous injection; Fixed doses starting with 0.1 mg/day in patients older than 55 years or patients weighing less than 50 kg; all other patients: 0.1 mg/day or 0.2 mg/day (these doses should all be lower than 0.04 mg/kg/week); all patients starting at 0.1 mg/day will have their dose progressively increased in 0.1 mg/day increments to a maximum clinically- and pharmacologically- tolerated plateau dose; all patients starting at 0.2 mg/day will increase in 0.2 mg/day increments; all incremented dose changes will occur at monthly intervals based on IGF-I levels; treatment will continue for 12 months
Study NCT01174043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be administered orally at 150 mg once a day, continuously. Each cycle will be 28 days and there will be no break between the cycles.
Study NCT01100528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: Given IV on days 1 and 29
Study NCT01100528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies obtained prior to therapy, every 8 weeks while on therapy, and then every 6 months during follow-up
Study NCT02750865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Embodied Conversational Agent (ECA)
Description: The ECA is a computer generated character who will interact with the subject on a daily basis via a touch-screen tablet. The system is designed to provide the following functions: (1) medication counseling; (2) physical activity promotion; (3) symptom management and continual screening for adverse events; and (4) alleviation of stress and anxiety. The investigators will augment the system to include: (5) spiritual needs assessment; and (6) advanced care planning.
Study NCT04438876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Power Training
Description: The exercise intervention encompassed high-velocity movement, balance, and mobility exercises with the use of body weight and resistance bands as resistance. Participants were instructed to move rapidly during the concentric phase and slowly during the eccentric phase when performing the dynamic exercises.
Study NCT04438876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants either continued the usual exercise program provided by their respective community senior activity centers or their personal exercise routine.
Study NCT03597477 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine
Description: participants were randomly allocated to receive sedation with oral midazolam(0.3 mg/kg) combined with 4 doses of intranasal dexmedetomidine(1.0, 1.5, 2.0, 2.5)
Study NCT00846989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RKI983A
Description: RKI983 0.05 % twice daily
Study NCT00846989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RKI983A
Description: RKI983 0.1 % twice daily
Study NCT00846989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: Latanoprost 0.005 % once a day
Study NCT05004506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block
Description: The anesthesia provider will identify the adductor canal using ultrasound guidance and inject 15ccs of 0.5% marcaine with epinephrine around the saphenous nerve.
Study NCT05004506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular Injection
Description: receive 20ccs of 2% lidocaine with epinephrine as an intra-articular injection
Study NCT00093886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clevidipine
Study NCT00093886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitroglycerin
Study NCT03808363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Participants assigned to this group will perform a very mild 5-minute warm-up (0 resistance, and 60 rpm), followed by 5 one-minute bouts of high intensity exercise, with 90 seconds between each bout. These bouts will be followed by a 3-minute cool down (0 resistance, and 60 rpm). The high-intensity exercise will be performed at an intensity of 17 on the Borg rating of perceived exertion (RPE) scale (very hard), and the 90 second active rest intervals will be performed at an intensity of 7-9 (very, very light - very light). The exercise will be performed on the NuStep machine 3 times a week for 6 weeks.
Study NCT01449773 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-3 PUFAs
Description: 5 capsules/day in order to provide 3 g/day of n-3 PUFAs.
Study NCT01449773 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 capsules/day containing corn and soybean oil
Study NCT03281551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PZ01 CAR-T cells
Description: Chimeric antigen receptor (CAR) T cells targeting CD19 will be evaluated for safety and efficacy in patients with relapsed/ refractory B-cell Acute Lymphoblastic Leukemia/B cell Lymphoma. The CAR consists of a CD19 targeting antibody scFv with two intracellular signaling domains derived from CD3 zeta and 4-1BB. Autologous T cells will be gene-engineered with the CAR gene using a lentivirus vector. Prior to T cell infusion, the patients will be subjected to preconditioning treatment. After T cell infusion, the patients will be evaluated for 24 months for adverse reactions, persistence of CAR T cells and efficacy.
Study NCT03747900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: 200 U Botulinum toxin type A injection in the spastic biceps brachii muscle.
Study NCT03747900 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A and dry needling.
Description: Dry needling for 4 times in total in the spastic biceps brachii muscle after the Botulinum toxin type A injection.
Study NCT04500236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Surgery under general anesthesia with the use of propofol
Study NCT04500236 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypno-analgesia
Description: Surgery under Hypnosis session and analgesics
Study NCT00933244 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High Dose Vitamin D3
Description: Yellow gel-cap vitamin D3 at 50,000 International Units daily for 15 days then two times a month for 350 days. Daily white placebo pills.
Study NCT00933244 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Low Dose Vitamin D3
Description: White gel-cap vitamin D3 at 800 International Units to take orally, daily for 365 days. Intermittent yellow placebo pills.
Study NCT00933244 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days. White gel-cap placebo pills once daily for 365 days.
Study NCT02227836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allergy Patch Testing
Study NCT02182674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Combivent HFA
Study NCT02182674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combivent HFA
Study NCT02182674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combivent (CFC)
Study NCT02182674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Combivent (CFC)
Study NCT05183269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oncomfort virtual reality monitor (Oncomfort SA, Wavre, Belgium)
Description: Use of the Oncomfort virtual reality monitor